Ocular Therapeutix, Inc. cash flow to debt ratio of -256.80% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ocular Therapeutix, Inc.'s free cash flow has decreased 59.52% from $-135.97M last year to $-216.89M, signaling decreasing performance

Ocular Therapeutix, Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability.

Ocular Therapeutix, Inc.'s debt has decreased relative to shareholder equity from 0.24 last year to 0.15 today, signaling strengthened financials

Ocular Therapeutix, Inc. has a net cash position, so leverage is healthy.

Ocular Therapeutix, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Ocular Therapeutix, Inc.'s profit margin has decreased (90.70%) in the last year from -303.67% to -579.10%, signaling decreasing performance

Ocular Therapeutix, Inc.'s short-term assets of $782.13M exceed its short-term liabilities of $50.81M

Ocular Therapeutix, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ocular Therapeutix, Inc.'s return on equity of -59.87%, is lower than 15.00%, indicating bad performance

Ocular Therapeutix, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ocular Therapeutix, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Ocular Therapeutix, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ocular Therapeutix, Inc. has negative free cash flow, indicating cash burn

Ocular Therapeutix, Inc.'s yearly earnings has decreased 37.43% since last year from $-193.51M to $-265.94M, signaling decreasing performance

Ocular Therapeutix, Inc.'s yearly revenue has decreased 18.67% since last year from $63.72M to $51.82M, signaling decreasing performance

ROIC -50.20% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ocular Therapeutix, Inc.'s 3-year revenue CAGR of 0.21% is positive, indicating growing revenue over the past 3 years

Ocular Therapeutix, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Ocular Therapeutix, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Ocular Therapeutix, Inc. has insufficient data to evaluate this check.

Ocular Therapeutix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ocular Therapeutix, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ocular Therapeutix, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ocular Therapeutix, Inc. has insufficient data to evaluate this check.

Ocular Therapeutix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ocular Therapeutix, Inc. has a price-to-book ratio of 4.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Ocular Therapeutix, Inc. has a price-to-sales ratio of 39.93x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue